
ABOUT SAMSUNG BIOLOGICS
Samsung Biologics is a full-service provider offering development and cGMP manufacturing services. We deliver a broad range of services from development and manufacturing to fill and finish, covering both clinical molecules and commercial products. Established in April 2011, Samsung Biologics will transform the global healthcare industry over the next decade through our quality, technology and innovation. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services (characterization, comparability, IPC, lot release & stability), and clinical and commercial bulk cGMP manufacturing of drug substance and drug product. We also provide quality assurance and quality control services, as well as worldwide regulatory compliance standards & support for our customers. We are centrally located in the heart of Asia, within 20 minutes of Incheon International Airport.
CONTACT INFORMATION
Samsung Biologics
300 Songdo Bio Way, Yeonsu-gu
Incheon, 21987
KOREA, REPUBLIC OF
Phone: +82 32 455 3114
Contact: Jinyong Kim
BROCHURES
- Organoid-Based Drug Screening Services
- Building On Excellence, Powering What's Next
- Ensure Success From An Early Stage: DEVELOPICK™
- Super Plant 4
- Plant 5 — Dream Plant: Within Your Reach. Built For Your Success.
- CDO Services: Agile. Flexible. Focused On You.
- Why Samsung Biologics?
- Trusted End-To-End CDMO Partner For Your Journey
- Antibody Drug Conjugates: Link Your Antibody To Its Fullest Potential
- The Power Of One: mRNA Services
- Customized CMC Solutions
- Aseptic Fill/Finish Service
- Leveraging Proprietary CDO Platforms
- The Choice For Your Next Dual-Specificity Therapeutics: S-DUAL™
- Capacity To Secure Your Success
FEATURED ARTICLES
- Biomanufacturing Readiness: A Validation Model For Multiproduct Facilities
- Utilizing Small-Scale Downstream Studies Across Biologics Manufacturing
- BsAb Development With Structural Innovation, Enhanced Manufacturability
- Strategic Biomanufacturing Partner For Multispecific Antibodies
- Optimizing DSP Development: Faster Timelines, Lower Costs, And High-Quality Processes
- Overcoming Challenges To High-Concentration Formulation Development
- Understanding And Mitigating Oxygen Heterogeneity In Large-Scale Bioreactors
- AI Implementation To Enhance Quality
- Enabling Digital Twins With Computational Fluid Dynamics Modeling
- Optimizing Bioprocesses Using Functional DOE
- A 5-Factor Framework For Successful CMO Partnership
- Mitigating Early Development Risks
- Improving Therapeutic Protein Efficacy Through Charge Profile Adjustment
- Leveraging Optimized Transient Expression For Material Generation And Early Stage Insight
- Embracing Quality-By-Design For Enhanced Development Strategies
- Streamlining Single-Use Assemblies In The Bulk-Fill Step Of Downstream Processing
- Reducing ADC Timelines With Integrated Development And Manufacturing
- Accelerating The Development And Production Of High-Quality bsAbs
- Optimizing Sialic Acid Clone Screening
- Addressing And Adapting To Evolving mRNA Market Trends
WEBINARS
- Streamlining Drug Development: From Developability Assessment To High-Concentration Formulation Development
- CLD To Upstream Optimization: Enhancing Biologics Quality, Productivity
- Bioprocess Optimization: Leveraging Functional DOE With Time-Based Insights
- Introducing 2 New Highly Effective ADC Payloads For Cancer Therapeutics
- Navigating Challenges During Formulation Development
- Formulation Considerations For The Development Of High Concentration Biopharmaceuticals
- Mitigating Early Development Risks With Samsung Biologics DEVELOPICK™ Platform
- Downstream Strategies To Accelerate Preclinical Development Timelines
- Enhancing Quality By Employing Cell Line Replacement, Process Optimization
- Continuous Manufacturing: Challenges, Advantages Of N-1 Perfusion
- Accelerated Tech Transfer For A COVID-19 Program
- Biopharmaceutical Process Characterization
- Key Considerations When Outsourcing An Aseptic Fill/Finish Project To A CMO Partner
- How COVID-19 Is Redefining Drug Development And Manufacturing
- All Eyes On mRNA: Addressing Key Insights Into The Next Blockbuster
- What To Consider In Selecting The Best Cell Line To Accelerate The Timeline To IND
- Get To IND Faster